Table 1 Levels of circulating soluble RAGE in cardiovascular and metabolic diseases.
From: RAGE and Soluble RAGE: Potential Therapeutic Targets for Cardiovascular Diseases
References | ||
|---|---|---|
sRAGE | Â | Â |
Coronary artery disease (nondiabetes) | Decreased | |
| Â | Increased | (68) |
Diabetes (type 1) | Increased | (66) |
Diabetes (type 2) | Increased | |
| Â | Decreased | |
Hypertension | Decreased | (63) |
Alzheimer disease | Decreased | (54) |
Chronic kidney disease | Increased | |
Oxidative stress and inflammatory markers | Positive association | |
| Â | Inverse association | (65) |
esRAGE | Â | Â |
Metabolic syndrome | Decreased | (56) |
Diabetes (type 1) | Decreased | |
Diabetes (type 2) | Decreased | (56) |
Hypertension | Decreased | (56) |
Atherosclerosis (IMT) | Inverse association | |
| Â | No association | (57) |
Chronic kidney disease | Increased | |